Treace Medical Q1 revenue falls 10%, less than expected

Treace Medical Concepts

08/05/2026 12:13

Overview

US bunion surgery device maker's Q1 revenue fell 10% yr/yr, beating analyst expectations

Company posted wider net loss and adjusted EBITDA loss compared to prior year

Full-year 2026 revenue guidance reaffirmed, projecting up to 5% decline or flat performance

Outlook

Treace reaffirms 2026 revenue guidance of $202 mln to $212 mln, down 5% to flat vs 2025

Company reiterates 2026 adjusted EBITDA loss forecast of $4 mln to $6 mln

Treace expects 2026 cash usage to decline about 50% from 2025

Result Drivers

CASE VOLUME GROWTH - Co said it continued to grow year-over-year case volumes and take market share

PRODUCT AND PRICE MIX HEADWINDS - Co said revenue was offset by continued headwinds from demand driven product and price mix shift within its expanded product portfolio

NEW PRODUCT LAUNCH - Co initiated limited market release of SuperBite Compression Screw System with successful first commercial cases

Company press release: ID:nGNX9pVkSH

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$47.20 mln
$45.96 mln (5 Analysts)
Q1 EPS
-$0.28
Q1 Gross Margin
79.30%
Q1 Gross Profit
$37.41 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Treace Medical Concepts, Inc is $3.00, about 56.3% above its May 7 closing price of $1.92

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)